CPRX Estados financieros: Análisis de Catalyst Pharmaceuticals Inc AI

Inicio

Acciones

CPRX

CPRX Financiero

Catalyst Pharmaceuticals Inc

$24.33

3.09%

$0.72

Al cierre: Feb 13, 16:00:00 GMT-5

$24

-1.35%

$-0.32

Mercado Posterior: Feb 13, 20:00:00 GMT-5

Visión general Pronóstico Ganando Dividendos Finanzas

Ingreso

Balance general

Flujo de efectivo

Anual

Trimestral

CPRX Ingreso

Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Ingresos	578	491	398	214	140	119
Crecimiento de los Ingresos (YoY)	26%	23%	86%	53%	18%	17%
Costo de los ingresos	83	68	51	34	21	17
Utilidad bruta	495	422	346	179	118	102
Venta, General y Administración	184	177	133	58	49	44
Investigación y Desarrollo	14	12	93	19	16	16
Gastos de Operación	236	227	259	78	66	60
Otras Ingresos (Gastos) No Operativos	26	21	7	2	0	0
Ingreso antes de impuestos	285	216	94	104	52	41
Gasto por Impuesto a la Renta	67	52	23	21	13	-33
Ingreso Neto	217	163	71	83	39	75
Crecimiento de la Utilidad Neta	52%	130%	-14%	112.99%	-48%	142%
Acciones en Circulación (Diluidas)	127.09	124.94	113.75	111.4	107.8	106.2
Cambio de Acciones (YoY)	2%	10%	2%	3%	2%	0%
EPS (Diluido)	1.71	1.31	0.62	0.75	0.37	0.71
Crecimiento de EPS	50%	109%	-16%	103%	-48%	137%
Flujo de efectivo libre	234	239	143	116	59	45
Flujo de efectivo libre por acción	--	--	--	--	--	--
Margen bruto	85.64%	85.94%	86.93%	83.64%	84.28%	85.71%
Margen de operación	44.63%	39.71%	21.6%	47.19%	37.14%	34.45%
Margen de beneficio	37.54%	33.19%	17.83%	38.78%	27.85%	63.02%
Margen de flujo de caja libre	40.48%	48.67%	35.92%	54.2%	42.14%	37.81%
EBITDA	295	232	118	102	52	41
Margen de EBITDA	51.03%	47.25%	29.64%	47.66%	37.14%	34.45%
D&A para EBITDA	37	37	32	1	0	0
EBIT	258	195	86	101	52	41
Margen de EBIT	44.63%	39.71%	21.6%	47.19%	37.14%	34.45%
Tasa de Impuesto Efectiva	23.5%	24.07%	24.46%	20.19%	25%	-80.48%

Estadísticas clave

Cierre Anterior

$23.6

Precio de apertura

$23.67

Rango del día

$23.65 - $24.67

Rango de 52 semanas

$19.05 - $26.58

Volumen

1.1M

Volumen promedio

1.2M

EPS (TTM)

1.72

Rendimiento de dividendos

Cap. de mercado

$2.9B

¿Qué es CPRX?

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company is headquartered in Coral Gables, Florida and currently employs 181 full-time employees. The company went IPO on 2006-11-08. The firm markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.



Características

Copiloto de IA para Acciones y Criptomonedas

Predicción de precios

Seguimiento de Recaudación de Fondos

Temas

Comparación de Criptomonedas

Recursos